Mesotherapy: Safety profile and management of complications.
complications
management
mesotherapy
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
18
12
2018
revised:
20
06
2019
accepted:
01
08
2019
pubmed:
25
8
2019
medline:
6
5
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Mesotherapy is a procedure that involves the injection of active substances into the dermis and subcutaneous tissue in order to treat several local medical and cosmetic conditions. Despite being considered as a relatively safe method, a series of adverse reactions can occur due to its wide application and lack of standardization processes. The aim of this paper is to summarize all the mesotherapy-related complications published so far, and to provide an insight into their management. Articles derived from the databases, PubMed, EMBASE, and SCOPUS, and published between 1992 and 2018, were analyzed for this review. The study was conducted according to the PRISMA guidelines. In this literature, there is a number of case series and isolated case reports describing various side effects of different severities. The therapeutic management of these complications is-in most cases-individualized. Larger systematic studies are needed in order to adequately evaluate the safety profile of mesotherapy, and in order to determine standardized therapy parameters, so as to minimize the risk of potential adverse reactions.
Sections du résumé
BACKGROUND
BACKGROUND
Mesotherapy is a procedure that involves the injection of active substances into the dermis and subcutaneous tissue in order to treat several local medical and cosmetic conditions. Despite being considered as a relatively safe method, a series of adverse reactions can occur due to its wide application and lack of standardization processes.
OBJECTIVES
OBJECTIVE
The aim of this paper is to summarize all the mesotherapy-related complications published so far, and to provide an insight into their management.
PATIENT/METHODS
METHODS
Articles derived from the databases, PubMed, EMBASE, and SCOPUS, and published between 1992 and 2018, were analyzed for this review. The study was conducted according to the PRISMA guidelines.
RESULTS
RESULTS
In this literature, there is a number of case series and isolated case reports describing various side effects of different severities. The therapeutic management of these complications is-in most cases-individualized.
CONCLUSIONS
CONCLUSIONS
Larger systematic studies are needed in order to adequately evaluate the safety profile of mesotherapy, and in order to determine standardized therapy parameters, so as to minimize the risk of potential adverse reactions.
Substances chimiques
Anti-Bacterial Agents
0
Drug Combinations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1601-1605Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Kim JT, Choi A, Jeong JH, et al. Safety evaluation and consideration of 4 pin multi-needle for meso-therapy. Technol Health Care. 2018;26:291-306.
Markiewicz A, Zasada M, Erkiert-Polguj A, Wieckowska-Szakiel M, Budzisz E. An evaluation of the antiaging properties of strawberry hydrolysate treatment enriched with L-ascorbic acid applied with microneedle mesotherapy. J Cosmet Dermatol. 2019;18:129-135.
Wermeling DP, Banks SL, Hudson DA, et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci. 2008;105:2058-2063.
Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf. 2018;17:1115-1128.
Arenbergerova M, Arenberger P, Gkalpakiotis S, Dahmen RA, Sticova E, Fialova A. Scalp melanoma after antihair loss mesotherapy. J Eur Acad Dermatol Venereol. 2018;32(5):e187-e188.
Orjuela D, Puerto G, Mejía G, et al. Cutaneous tuberculosis after mesotherapy: report of six cases. Biomedica. 2010;30:321-326.
Centers for Disease Control and Prevention (CDC). Outbreak of mesotherapy-associated skin reactions-district of Columbia area, january-february 2005. MMWR Morb Mortal Wkly Rep. 2005;54(44):1127-1130.
Galmés-Truyols A, Giménez-Duran J, Bosch-Isabel C, et al. An outbreak of cutaneous infection due to Mycobacterium abscessus associated to mesotherapy. Enferm Infecc Microbiol Clin. 2011;29:510-514.
Wongkitisophon P, Rattanakaemakorn P, Tanrattanakorn S, Vachiramon V. Cutaneous Mycobacterium abscessus infection associated with mesotherapy injection. Case Rep Dermatol. 2011;3:37-41.
Da Mata JO, Hernández-Pérez R, Corrales H, Cardoso-Leao S, de Waard JH. Follow-up on an outbreak in Venezuela of soft-tissue infection due to Mycobacterium abscessus associated with mesotherapy. Enferm Infecc Microbiol Clin. 2010;28:596-601.
Couderc C, Carbonne A, Thiolet JM, et al. Non-tuberculous mycobacterial infections related to esthetic care in France, 2001-2010. Med Mal Infect. 2011;41:379-383.
Correa NE, Cataño JC, Mejía GI, et al. Outbreak of mesotherapy-associated cutaneous infections caused by Mycobacterium chelonae in Colombia. Jpn J Infect Dis. 2010;63:143-145.
Regnier S, Cambau E, Meningaud JP, et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis. 2009;49:1358-1364.
Quiñones C, Ramalle-Gómara E, Perucha M, et al. An outbreak of Mycobacterium fortuitum cutaneous infection associated with mesotherapy. J Eur Acad Dermatol Venereol. 2010;24:604-606.
Nagore E, Ramos P, Botella-Estrada R, Ramos-Níguez JA, Sanmartín O, Castejón P. Cutaneous infection with Mycobacterium fortuitum after localized microinjections (mesotherapy) treated successfully with a triple drug regimen. Acta Derm Venereol. 2001;81:291-293.
Difonzo EM, Campanile GL, Vanzi L, Lotti L. Mesotherapy and cutaneous Mycobacterium fortuitum infection. Int J Dermatol. 2009;48:645-647.
Del-Castillo M, Palmero D, Lopez B, et al. Mesotherapy-associated outbreak caused by Mycobacterium immunogenum. Emerg Infect Dis. 2009;15:357-359.
Marco-Bonnet J, Beylot-Barry M, Texier-Maugein J, et al. Mycobacterial bovis BCG cutaneous infections following mesotherapy: 2 cases. Ann Dermatol Venereol. 2002;129:728-731.
Rodríguez-Gutiérrez G, Toussaint S, Hernández-Castro R, Sánchez-León Mdel C, Arenas R Nocardia brasiliensis infection: an emergent suppurative granuloma after mesotherapy. Int J Dermatol. 2014;53:888-890.
González F, Hernández C, Henao L, et al. Infección cutánea por Micobacterias y Nocardia asociada a mesoterpia. Vitae. 2004;20:1-7.
Gamo R, Aguilar A, Cuétara M, et al. Sporotrichosis following mesotherapy for arthrosis. Acta Derm Venereol. 2007;87:430-431.
Kutlubay Z, Gokalp H, Ince U, Engin B. Cutaneous foreign body granulomas associated with lipolytic cocktail: who is the enemy, mesotherapy or drugs injected? J Cosmet Laser Ther. 2017;19:310-312.
Alfaro-Rubio A, Martorell-Calatayud A, Pelufo C, Terradez L, Hueso-Gabriel L, GarciaMelgares ML. Mesotherapy granulomas with L-carnitine. American Academy of Dermatology 71st Annual Meeting. Florida, USA. 1-5 March 2013. PP-6919 (Poster).
Gokdemir G, Küçükünal A, Sakız D. Cutaneous granulomatous reaction from mesotherapy. Dermatol Surg. 2009;35:291-293.
Ramos-e-Silva M, Pereira AL, Ramos-e-Silva S, Piñeiro-Maceira J. Oleoma: rare complication of mesotherapy for cellulite. Int J Dermatol. 2012;51:162-167.
Strahan JE, Cohen JL, Chorny JA. Granuloma annulare as a complication of mesotherapy: a case report. Dermatol Surg. 2008;34:836-838.
Park EJ, Kim HS, Kim M, Oh HJ. Histological changes after treatment for localized fat deposits with phosphatidylcholine and sodium deoxycholate. J Cosmet Dermatol. 2013;12:240-243.
Polat M, Üstün H. A case of mesotherapy-induced panniculitis. Cutan Ocul Toxicol. 2016;35:163-164.
Tan J, Rao B. Mesotherapy-induced panniculitis treated with dapsone: case report and review of reported adverse effects of mesotherapy. J Cutan Med Surg. 2006;10:92-95.
Davis MD, Wright TI, Shehan JM. A complication of mesotherapy: noninfectious granulomatous panniculitis. Arch Dermatol. 2008;144:808-809.
Lee DP, Chang SE. Subcutaneous nodules showing fat necrosis owing to mesotherapy. Dermatol Surg. 2005;31:250-251.
Al-Khenaizan S. Cutaneous ulcers following mesotherapy. Dermatol Surg. 2008;34:832-4; discussion 834-5.
Kadry R, Hamadah I, Al-Issa A, Field L, Alrabiah F. Multifocal scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy. J Drugs Dermatol. 2008;7:72-73.
El-Komy M, Hassan A, Tawdy A, Solimon M, Hady MA. Hair loss at injection sites of mesotherapy for alopecia. J Cosmet Dermatol. 2017;16:e28-e30.
Duque-Estrada B, Vincenzi C, Misciali C, Tosti A. Alopecia secondary to mesotherapy. J Am Acad Dermatol. 2009;61:707-709.
Schmutz JL, Barbaud A, Trechot P. Alopecia and mesotherapy. Ann Dermatol Venereol. 2010;137:338.
Rallis E, Kintzoglou S, Moussatou V, Riga P. Mesotherapy-induced urticaria. Dermatol Surg. 2010;36:1355-1356.
Urbani CE. Urticarial reaction to ethylenediamine in aminophylline following mesotherapy. Contact Dermatitis. 1994;31:198-199.
Vaillant L, de Muret A, Muller C, Machet L, Lorette G. Lichenoid drug eruption after mesotherapy. Ann Dermatol Venereol. 1992;119:936-937.
Grojean MF, Vaillant L. Lichenoid eruption caused by mesotherapy. Ann Med Interne. 1995;146:365-366.
Babacan T, Onat AM, Pehlivan Y, Comez G, Tutar E. A case of the Behcet's disease diagnosed by the panniculits after mesotherapy. Rheumatol Int. 2010;30:1657-1659.
Rosina P, Chieregato C, Miccolis D, D'Onghia FS. Psoriasis and side-effects of mesotherapy. Int J Dermatol. 2001;40:581-583.
Bessis D, Guilhou JJ, Guillot B. Localized urticaria pigmentosa triggered by mesotherapy. Dermatology. 2004;209:343-344.
Colón-Soto M, Peredo RA, Vilá LM. Systemic lupus erythematosus after mesotherapy with acetyl-L-carnitine. J Clin Rheumatol. 2006;12:261-262.
Calonge WM, Lesbros-Pantoflickova D, Hodina M, Elias B. Massive subcutaneous emphysema after carbon dioxide mesotherapy. Aesthetic Plast Surg. 2013;37:194-197.
Zaragoza J, Delaplace M, Benamara M, Estève E. A rare side effect of mesotherapy: Nicolau syndrome. Ann Dermatol Venereol. 2013;140:713-717.
Vukcević NP, Babić G, Segrt Z, Ercegović GV, Janković S, Aćimović L. Severe acute caffeine poisoning due to intradermal injections: mesotherapy hazard. Vojnosanit Pregl. 2012;69:707-713. Erratum. In: Vojnosanit Pregl. 2012;69:929.
Danilovic DL, Bloise W, Knobel M, Marui S. Factitious thyrotoxicosis induced by mesotherapy: a case report. Thyroid. 2008;18:655-657.
Kim JB, Moon W, Park SJ, et al. Ischemic colitis after mesotherapy combined with anti-obesity medications. World J Gastroenterol. 2010;16:1537-1540.
Tor PC, Lee TS. Delirium with psychotic features possibly associated with mesotherapy. Psychosomatics. 2008;49:273-274.
Moftah N, Moftah N, Abd-Elaziz G, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27:686-693.
Brandão C, Fernandes N, Mesquita N, et al. Abdominal haematoma-a mesotherapy complication. Acta Derm Venereol. 2005;85:446.
Mammucari M, Lazzari M, Maggiori E, et al. Role of the informed consent, from mesotherapy to opioid therapy. Eur Rev Med Pharmacol Sci. 2014;18:566-574.